NRX Pharmaceuticals (NRXP) Short term Debt (2021 - 2025)

NRX Pharmaceuticals (NRXP) has 4 years of Short term Debt data on file, last reported at $152000.0 in Q3 2025.

• On a quarterly basis, Short term Debt fell 76.03% year-over-year to $152000.0 in Q3 2025; TTM through Sep 2025 was $152000.0, a 76.03% decrease from a year earlier, with the FY2024 full-year figure at $320000.0, changed N/A from the prior year.
• Short term Debt for Q3 2025 stood at $152000.0, down from $378000.0 in the prior quarter.
• Over the last five years, Short term Debt for NRXP reached as high as $26.3 million in Q3 2021 and fell as low as $152000.0 in Q3 2025.
• Historically, Short term Debt has averaged $6.8 million across 4 years, with a median of $943000.0 in 2024.
• On a YoY basis, Short term Debt climbed as much as 59.92% in 2025 and fell as far as 76.03% in 2025.
• Year by year, Short term Debt stood at $4.6 million in 2021, then plunged by 45.9% to $2.5 million in 2022, then sank by 87.09% to $320000.0 in 2024, then tumbled by 52.5% to $152000.0 in 2025.
• Per Business Quant data, the three most recent Short term Debt figures were $152000.0 in Q3 2025, $378000.0 in Q2 2025, and $320000.0 in Q4 2024.